Dr. Tiara T. Wong is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovation practice. She assists with the preparation and prosecution of patent applications in the life sciences, biotechnology, and pharmaceutical fields.
Prior to joining the firm, Tiara was a scientist at AnaBios Corporation, a contract research organization utilizing human primary cells and tissues for drug discovery. She worked on several research and development projects that supported clients' needs. Her works involved human precision-cut lung slices (PCLS), spinal cord slices, cardiomyocytes, and dorsal root ganglia (DRGs). She also assisted the calcium imaging department on pain pathway studies using DRGs. Through her career in science, Tiara acquired broad experience in the field of life sciences, including molecular biology, cell biology, stem cell biology, cancer biology, immunology, neurobiology, cardiovascular diseases, and in vitro disease models.
Tiara received her Ph.D. in biomedical sciences from Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California, where her work focused on using patient specific induced pluripotent stem cells (iPSC) to model a fibrotic phenotype of a genetic heart disease called ARVD/C.
Tiara is fluent in English and Thai.
Dr. Tiara T. Wong is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovation practice. She assists with the preparation and prosecution of patent applications in the life sciences, biotechnology, and pharmaceutical fields.
Prior to joining the firm, Tiara was a scientist at AnaBios Corporation, a contract research organization utilizing human primary cells and tissues for drug discovery. She worked on several research and development projects that supported clients' needs. Her works involved human precision-cut lung slices (PCLS), spinal cord slices, cardiomyocytes, and dorsal root ganglia (DRGs). She also assisted the calcium imaging department on pain pathway studies using DRGs. Through her career in science, Tiara acquired broad experience in the field of life sciences, including molecular biology, cell biology, stem cell biology, cancer biology, immunology, neurobiology, cardiovascular diseases, and in vitro disease models.
Tiara received her Ph.D. in biomedical sciences from Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California, where her work focused on using patient specific induced pluripotent stem cells (iPSC) to model a fibrotic phenotype of a genetic heart disease called ARVD/C.
Tiara is fluent in English and Thai.
- Ph.D., Biomedical Sciences, Sanford Burnham Prebys Medical Discovery Institute, 2018
- B.A., Biology, McDaniel College, 2012
Specialization in Molecular Biology, Summa Cum Laude, With Honors in Biology
- U.S. Patent and Trademark Office
- Ph.D., Biomedical Sciences, Sanford Burnham Prebys Medical Discovery Institute, 2018
- B.A., Biology, McDaniel College, 2012
Specialization in Molecular Biology, Summa Cum Laude, With Honors in Biology
- U.S. Patent and Trademark Office
Select Publications
- Co-author with A.T. Ton, et al., "Arrhythmogenic and Antiarrhythmic Actions of Late Sustained Sodium Current in The Adult Human Heart," Scientific Report, 2021
- Co-author with J.P. Song, et al., "Elevated Plasma Beta-Hydroxybutyrate Predicts Adverse Outcomes and Disease Progression in Patients with Arrhythmogenic Cardiomyopathy," Science Translational Medicine, 2020
- Co-author with K. Shah, et al., "Modeling Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy with Patient-Specific iPSCs," Chapter 3, Human iPSC Cells in Disease Modeling, edited by K. Fukada, 2016
- Co-author with W. Leung, et al., "The Drosophila Muller F Elements Maintain a Distinct Set of Genomic Properties Over 40 Million Years of Evolution," G3: GENES, GENOMES, GENETICS, 2015
- Co-author with C. Cerrone, et al., "Missense Mutations in Plakophilin-2 Cause Sodium Current Deficit and Associate with a Brugada Syndrome Phenotype," Circulation, 2013
Select Publications
- Co-author with A.T. Ton, et al., "Arrhythmogenic and Antiarrhythmic Actions of Late Sustained Sodium Current in The Adult Human Heart," Scientific Report, 2021
- Co-author with J.P. Song, et al., "Elevated Plasma Beta-Hydroxybutyrate Predicts Adverse Outcomes and Disease Progression in Patients with Arrhythmogenic Cardiomyopathy," Science Translational Medicine, 2020
- Co-author with K. Shah, et al., "Modeling Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy with Patient-Specific iPSCs," Chapter 3, Human iPSC Cells in Disease Modeling, edited by K. Fukada, 2016
- Co-author with W. Leung, et al., "The Drosophila Muller F Elements Maintain a Distinct Set of Genomic Properties Over 40 Million Years of Evolution," G3: GENES, GENOMES, GENETICS, 2015
- Co-author with C. Cerrone, et al., "Missense Mutations in Plakophilin-2 Cause Sodium Current Deficit and Associate with a Brugada Syndrome Phenotype," Circulation, 2013
The proceeds from the financing will be used to advance the clinical development of two drugs: SM-020, a topical novel AKT kinase inhibitor for the treatment of seborrheic keratoses (SKs), and SM-030, a topical novel PKC-beta inhibitor for the treatment of melasma and other hyperpigmentation disorders of the skin. They are expected to fund the company through end of its Phase 2 meetings with the U.S. Food and Drug Administration (FDA), which are expected in the second half of 2024 for both programs.
Wilson Sonsini has represented DermBiont on IP matters since the company’s inception, and the patent team that advised on the Series B included Matt Bresnahan, Alicia Umpierre, Dalton Case, and Tiara Wong. The Wilson Sonsini corporate team that advised on the transaction included Jason Skolnik, Dani Glazer Signaigo, and Leila Purqurian.
For more information, please see DermBiont’s news release.
- Privacy Policy
- Terms of Use
- Accessibility